Davis Polk advised the joint book-running managers in connection with a $124.5 million SEC-registered follow-on offering of 3,000,000 shares of common stock of Adamas Pharmaceuticals, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “ADMS.”

Based in Emeryville, California, Adamas Pharmaceuticals, Inc. is a biopharmaceutical company committed to developing and commercializing products and product candidates for the treatment of chronic neurological disorders.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Marcus K. Hintze, Amy Tu and Katherine Schloss Ackerman. The tax team included partner Rachel D. Kleinberg and associate Caroline E. Dayton. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices. 

Copy link to share post